晚期胃癌分子靶向治疗研究现状
| 作者: |
1赵鹏飞,
1曹邦伟
1 首都医科大学附属北京友谊医院肿瘤科，北京 100050 |
| 通讯: |
赵鹏飞
Email: perfei88@163.com 曹邦伟 Email: oncology@ccmu.edu.cn |
| DOI: | 10.3978/j.issn.2095-6959.2015.08.028 |
| 基金: | 北京市卫生系统高层次卫生技术人才项目, 2011-3-00 国家自然科学基金, 81272615、81301912 |
摘要
胃癌是全球第三大致死率的恶性肿瘤，在确诊时往往处于疾病中晚期阶段。目前许多研究均提示胃癌患者体细胞基因组存在异常。然而，尽管目前胃癌基因组学特性方面取得很多进展，但病人预后并无明显改善。对于进展期/晚期胃癌(advanced gastric cancer，AGC)患者，中位生存时间仅维持在12个月左右。曲妥珠单抗、雷莫芦单抗(ramucirumab)、阿帕替尼(apatinib)等的出现显示出胃癌分子靶向治疗的希望及针对肿瘤分子生物靶向治疗的重要性。本文就目前AGC分子靶向治疗的研究现状简要综述。
关键词：
晚期胃癌
靶向治疗
临床试验
Molecule target therapies in advanced gastric cancer
CorrespondingAuthor: ZHAO Pengfei Email: perfei88@163.com
DOI: 10.3978/j.issn.2095-6959.2015.08.028
Abstract
Gastric cancer is the third leading cause of cancer death worldwide and the majority of patients are diagnosed with stage III or IV. Recently many researchers discover that somatic genomic aberrations exist in gastric cancer; however, despite there are many advances in genomics of gastric cancer, there is no evidently improvement in patients’ outcomes. Prognosis remains poor with a median overall survival of 12 months for patients with advanced gastric cancer. The improved survival with trastuzumab, ramucirumab and apatinib displayed the promise and importance of molecular targeted therapies in gastric cancer. Here we review the current study status and ongoing clinical trials of molecule target drugs of gastric cancer briefly.